Search

Cellphone “selfies” distort facial features, an effect that may be driving an uptick in requests for plastic surgery, UT Southwestern researchers show in a new study.

Patients with a family history of age-related macular degeneration (AMD), the leading cause of permanent vision loss in those older than 60, should visit an ophthalmologist by age 55 to be screened for signs of the disease, advises an expert at UT Southwestern Medical Center.

A new study by the Kidney Cancer Program (KCP) at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center shows that highly focused radiation to isolated metastases that progress despite drug therapy can prolong drug use in kidney cancer patients, saving the few other drugs for treating

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non-small cell lung cancers (NSCLCs) to respond to an immune checkpoint blockade (ICB), a therapy that harnesses the immune system to fight malignant tumors.

As you drift into unconsciousness before a surgery, general anesthetic drugs flowing through your blood are putting you to sleep by binding mainly to a protein in the brain called the ɣ-aminobutyric acid type A (GABAA) receptor.

An estimated one-quarter of adults in the U.S. have nonalcoholic fatty liver disease (NAFLD), an excess of fat in liver cells that can cause chronic inflammation and liver damage, increasing the risk of liver cancer.

A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.

UT Southwestern researchers have identified the molecular function of 87 inherited genetic variants that affect the risk of prostate cancer, and the majority appear to control the activity of genes located far away from the risk variants themselves.

Led by two UT Southwestern physicians, a team of researchers from 15 U.S. medical centers has performed the first analysis of a potentially game-changing drug to treat upper urinary tract urothelial cancers.

When McKinney real estate developer John Hill was 35, his father died of prostate cancer. The elder Mr. Hill had undergone surgery to remove his prostate a few years earlier, but the cancer had already spread.